Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
July 25, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast...
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
June 26, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Funding from second closing extends cash runway to mid-2025 to advance the company’s HSC gene therapy portfolio through several potential value-creating milestones OTL-200 (MLD) BLA submission...
Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
May 24, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, May 24, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at Stifel’s...
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
May 19, 2023 09:00 ET
|
Orchard Therapeutics (Europe) Limited
New OTL-203 proof-of-concept data demonstrate extensive metabolic correction in the skeletal system of patients with MPS-IH including normal growth rates, improvement in joint function and progressive...
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
May 18, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of...
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
May 15, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data...
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
May 03, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Six presentations showcase the differentiated profile and broad applicability of the company’s HSC gene therapy platform Oral presentations in MPS-IH and MPS-IIIA and the progranulin form of...
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
March 30, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the...
Orchard Therapeutics Completes ADS Ratio Change
March 10, 2023 10:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its...
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
March 06, 2023 06:05 ET
|
Orchard Therapeutics (Europe) Limited
OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare...